By continuing to browse this site you agree to us using cookies as described in About Cookies
Notice: Due to essential maintenance the subscribe/renew pages will be unavailable on Wednesday 26 October between 02:00- 08:00 BST/ 09:00 – 15:00 SGT/ 21:00- 03:00 EDT. Apologies for the inconvenience.
Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Address reprint requests to: Raymond T. Chung, M.D., Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, 55 Fruit St., Warren 1007, Boston, MA 02114. E-mail: email@example.com; fax: 617-643-0446.
Potential conflict of interest: Nothing to report.
Supported by NIH AI082630 (RTC), and by the Deutsche Forschungsgemeinschaft (German Research Foundation, DFG) research fellowship Ji 145/1-1 (NJ).
Several genome-wide association studies (GWAS) have identified a genetic polymorphism associated with the gene locus for interleukin 28B (IL28B), a type III interferon (IFN), as a major predictor of clinical outcome in hepatitis C. Antiviral effects of the type III IFN family have previously been shown against several viruses, including hepatitis C virus (HCV), and resemble the function of type I IFN including utilization of the intracellular Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway. Effects unique to IL28B that would distinguish it from IFN-α are not well defined. By analyzing the transcriptomes of primary human hepatocytes (PHH) treated with IFN-α or IL28B, we sought to identify functional differences between IFN-α and IL28B to better understand the roles of these cytokines in the innate immune response. Although our data did not reveal distinct gene signatures, we detected striking kinetic differences between IFN-α and IL28B stimulation for interferon stimulated genes (ISGs). While gene induction was rapid and peaked at 8 hours of stimulation with IFN-α in PHH, IL28B produced a slower, but more sustained increase in gene expression. We confirmed these findings in the human hepatoma cell line Huh7.5.1. Interestingly, in HCV-infected cells the rapid response after stimulation with IFN-α was blunted, and the induction pattern resembled that caused by IL28B. Conclusion: The kinetics of gene induction are fundamentally different for stimulations with either IFN-α or IL28B in hepatocytes, suggesting distinct roles of these cytokines within the immune response. Furthermore, the observed differences are substantially altered by infection with HCV. (Hepatology 2014;59:1250-1261)
Janus kinase signal transducer and activator of transcription
primary human hepatocytes
quantitative polymerase chain reaction
reverse transcription PCR
single nucleotide polymorphism
In 2003, a novel family of antiviral cytokines was described and designated type III interferons.[1, 2] Since their discovery, the three members comprising this family, interleukin (IL) 28A, also known as interferon (IFN) λ2, IL28B (IFN-λ3), and IL29 (IFN-λ1) have been extensively studied and have in many respects been found to resemble type I interferons. While type III interferons bind to a receptor complex that is distinct from the interferon-α receptor, type I and III interferons have been shown to share a common downstream signaling pathway by way of Janus kinase signal transducer and activator of transcription (JAK-STAT), leading to the induction of interferon stimulated genes (ISGs), like OAS1.
In contrast to the type I interferon receptor that is expressed ubiquitously on mammalian cells, the functional type III interferon receptor appears to be more tissue restricted with preferential expression on the surfaces of epithelial cells, including hepatocytes.
Chronic hepatitis C virus (HCV) is estimated to affect 2%-3% of the world's population and is currently the leading cause of both hepatocellular carcinoma and liver transplantations in both the U.S. and Europe.[5, 6] Peginterferon based therapies have been the mainstay of HCV therapy for nearly a decade. However, they are fraught with an unfavorable side effect profile, long duration of treatment, a limited success rate, and high costs. Furthermore, many patients have contraindications to treatment with peginterferon. The parameters that determine therapeutic success or failure in patients treated for HCV are still incompletely understood.
A recent breakthrough in the field was the discovery that genetic variation in the proximity of the IL28B (otherwise known as IFN-λ3) gene is a major predictor of successful therapy with peginterferon and ribavirin.[8-10] In addition, the detected IL28B-associated single nucleotide polymorphisms (SNPs) have been shown to significantly determine spontaneous viral clearance.[11, 13] Coupled with the extremely strong correlation between IL28B genotype, the previously known antiviral effect of the IL28B protein makes an important role of the gene product in the course of HCV highly likely. However, the mechanism by which the genetic polymorphism impacts the outcome of viral infection is unknown; thus, further studies to elucidate the mechanism are needed.
Recently, we have shown that IL28B inhibits HCV replication in a hepatoma cell line and that this action depends on an intact JAK-STAT pathway. Thus, IL28B's action seems to resemble the effects of its close relatives IL28A and IL29 as well as IFN-α. While this study was important in order to establish that IL28B, like IL28A, IL29, and IFN is mainly signaling through the JAK-STAT pathway, it did not provide further insight regarding the unique contribution of IL28B in the response to HCV infection and therapy observed in the original genome-wide association studies (GWAS).
In an effort to identify functional differences between the effects of IL28B and IFN-α, we compared the transcriptomes of IL28B and IFN-α stimulated primary human hepatocytes at different doses and over different periods of time. We tested the hypothesis that there are distinct differences in the gene expression patterns of hepatocytes upon stimulation with IFN-α and IL28B, respectively, and that these differences could play a role in differential downstream antiviral action.
Materials and Methods
Cell Cultures and Viruses
The human hepatoma cell line Huh7.5.1 was grown at 37°C in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin (HyClone Laboratories, South Logan, UT). Viral RNA was made from plasmid Jc1FLAG2(p7-nsGluc2a), which represents an infectious recombinant HCV strain (based on Jc1), that harbors the Gaussia luciferase gene, and the RNA was transfected as previously described. Briefly, we used electroporation for the transfection of Jc1FLAG2(p7-nsGluc2a) RNA into Huh7.5.1 cells and collected the supernatants at day 3 posttransfection. We then used these supernatants to inoculate naïve Huh7.5.1 cells with a tissue culture infectious dose 50 (TCID50) of 3.24 × 104/mL. TCID50 was determined using the method described by Lindenbach et al. with an antibody against HCV core protein. Infection was confirmed by quantitative polymerase chain reaction (qPCR) for viral RNA and western blotting for HCV core protein, and infection with Jc1FLAG2(p7-nsGluc2a) by luciferase assay and qPCR for viral RNA. Primary human hepatocytes (PHH) were obtained after liver resections from three donors for colorectal metastasis from apparently healthy excess liver tissue portions that were not required for pathological diagnosis and therefore discarded if not used for research purposes. Liver resections were received from the University of Pittsburgh through the Liver Tissue and Procurement and Distribution System (LTPADS; Dr. Stephen C. Strom, Pittsburgh, PA) and were isolated under the Institutional Review Board guidelines of the University of Pittsburgh as described. PHH were cultured in HMM (hepatocyte maintenance medium; Lonza, Walkersville, MD) supplemented with HMM Single Quots Kit, except that gentamycin was replaced by 100 U/mL penicillin and 100 μg/mL streptomycin (HyClone Laboratories). The hepatocytes in the microarray experiments were genotyped for an IL28B associated polymorphism at rs12979860 and we obtained the following results: C/C (1602), C/T (1638), T/T (1649).
Peginterferon alfa-2b was obtained from Schering (Kenilworth, NJ). For the microarray studies in PHH, we used IL28B derived from an expression system as described. After the protein became commercially available, we used human IL28B from R&D Systems (Minneapolis, MN). We used 0.21 ng/mL peginterferon alfa-2b (equivalent to 6.91 × 10-6 nmol/mL or 15 IU/mL) and 1,000 ng/mL IL28B (4.97 × 10-2 nmol/mL) for the stimulation of PHH. Doses for the Huh7.5.1 cells were 0.43 ng/mL (1.38 × 10-5 nmol/mL or 30 IU/mL) IFN-α and 50 ng/mL (7.46 × 10-4 nmol/l) IL28B.
For extraction of total RNA, cells were lysed and processed with the QIA shredder and RNeasy kits (Qiagen, Valencia, CA) according to the manufacturer's protocol. RNA was reconstituted and stored in RNase free water. RNA concentrations were measured using the NanoDrop spectrophotometer (Thermo Scientific NanoDrop Products, Wilmington, DE). For the microarrays, RNA quality was additionally tested by the Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA).
Total RNA was reverse transcribed to complementary DNA (cDNA) with random primers using the Applied Biosystems High Capacity cDNA Reverse Transcription Kit (Invitrogen, Carlsbad, CA). Specific cDNA levels were quantified by real-time PCR using the Bio-Rad IQ5 machine (Bio-Rad Laboratories, Hercules, CA) and Thermo Scientific DyNAmo HS SYBR green qPCR kit (Thermo Fisher Scientific, Waltham, MA). GAPDH expression was used as an internal reference. Primers for the qPCR experiments are listed in Table 1.
Table 1. Primer Sequences for Quantitative RT-PCR
Nucleotide Sequence (5′ to 3′)
F: forward; R: reverse.
The Illumina BeadChip HT-12 was used for microarray analysis according to the manufacturer's protocol (Illumina, San Diego, CA) and to the methods described in Urban et al. A single RNA sample was not available for further analysis and, therefore, no microarray data are available (1602/ IL28B/ 24 hours).
Protein sample preparation and western blotting were performed as described. The following antibodies were used: STAT1 (Tyr701) rabbit monoclonal, and STAT1 mouse monoclonal from Cell Signaling Technology (Beverly, MA), β-actin (A2228) mouse monoclonal from Sigma-Aldrich (St. Louis, MO), and the secondary antibodies antimouse IgG (NA931) and antirabbit IgG (N933, GE Healthcare).
Data analysis was carried out using a 2-tailed Student t test with pooled variance. Data are expressed as mean ± SD of at least three sample replicates, unless stated otherwise. Microarray data was first analyzed as previously. For the identification of relevant interferon stimulated genes in the PHH microarrays, we used gene induction by IL28B at 4, 8, and 24 hours with a q-value (false discovery rate) ≤0.05. The hits were further analyzed by means of the database and web-tool STRING (Search Tool for the Retrieval of Interacting Genes/Proteins), a meta-resource that aggregates most of the available information on protein-protein associations, scores and weights it, and augments it with predicted interactions, as well as with the results of automatic literature-mining searches as described in Jensen et al. We fitted cubic splines to the expression data in Fig. 3 to demonstrate trends in expression kinetics.
Transcriptomes of Both IFN-α and IL28B Stimulated PHH Comprise Typical ISGs
In order to identify differential effects of IFN-α and IL28B on the hepatocyte, we sought to determine gene expression patterns using an unbiased approach by transcriptomic microarrays in the currently best model for the isolated study of this cell type, PHH cultures. Interestingly, the magnitude of induction was generally much lower for most interferon stimulated genes in PHH compared to hepatoma cells. We stimulated PHH from three different donors with either IFN-α or IL28B over a 24-hour time course, isolated RNA, and determined gene induction by expression microarrays (Fig. 1). We evaluated data from three different donors as described in the Materials and Methods. After sorting the genes by relevant induction by IL28B, we compared the expression of the same genes after IFN-α stimulation. Most of the genes with relevant induction represented known ISGs, which are by definition inducible by IFN-α, after stimulation with both IFN-α and IL28B (Fig. 2A), including OAS1, IFIT3, ISG15, and RSAD2 (Viperin). Many of the significantly induced genes are known to be coexpressed (Fig. 2B). Based on this observation, and in line with previous studies, we concluded that at least a majority of genes substantially induced by IL28B in PHH are shared with those induced by IFN-α, and are therefore typical ISGs. Hence, from these experiments we are not able to identify a unique expression signature of IL28B, which comprises distinct genes from those induced by IFN-α. These findings strongly suggest that IL28B and IFN-α have near complete overlap of signal transduction.
IFN-α Leads to a Rapid but Transient Increase of Gene Expression in PHH, Whereas IL28B Gene Induction Is Slower and Sustained
We next sought to determine the temporal nature of ISG induction by IFN-α and IL28B. When comparing the time courses of induction, we found that many of the IFN-α responsive genes, like MX1, OAS1, and IFI6, were induced at 4 hours, were further up-regulated at 8 hours, and showed lower expression at 24 hours compared to 8 hours. While these genes were also found to be induced by IL28B, the kinetic profile was markedly different: The signal increased steadily over 24 hours with the highest fold-induction value after the longest period of stimulation (Figs. 1,3). The lack of evidence for specific IL28B induced genes and the observation that transcriptomes of IFN-α and IL28B largely overlap in PHH made us consider alternative mechanisms as to how IFN-α and IL28B execute their distinct effects on hepatocytes. Indeed, we observed different kinetic profiles when analyzing induction of the same genes by IFN-α and IL28B. We therefore hypothesized that the two cytokines exert their differential effects on innate immunity temporally and therefore further investigated these differences. We analyzed a number of the ISGs induced on the microarrays, MX1 (Fig. 4A), OAS1 (Fig. 4B), RSAD2 (Viperin; Fig. 4C), STAT1 (Fig. 4D), and IRF9 (Fig. 4E), in qRT-PCR experiments from the same RNA extracts. While the magnitude of fold induction differed substantially between genes, the chosen doses led to graphs similar in range for IFN-α and IL28B. We were able to confirm induction of these ISGs by both IFN-α and IL28B on qPCR. As observed in the microarray experiments, we demonstrated that within 24 hours for all but one sample there was maximum induction after 8 hours of treatment with IFN-α, whereas during the same period IL28B led to a monotonic increase of expression. The one exception was a slight shift of the peak to 4 hours in the PHH from one of the donors in IRF9 induction (Fig. 4E).
Typical Patterns of ISG Induction by IFN-α and IL28B Over Time Are Preserved in Huh7.5.1 Cells
While regarded a model closely resembling the in vivo situation in many respects, PHH cultured in a monolayer has several limitations. They do not proliferate, rapidly lose cell function, and are only viable for a limited number of days. Moreover, we found that when the hepatoma cell line Huh7.5.1 was used as a robust in vitro model for hepatocytes, the magnitude of ISG induction is much higher than in PHH and therefore permits detection of expression differences below a threshold value or below level of detection in PHH. Hence, we chose several of the top induced genes from the microarray experiments and further studied them in Huh7.5.1 cells (Fig. 5). After initial dose finding experiments, we submitted Huh7.5.1 cells to a time course over 48 hours of stimulation with IFN-α and IL28B (data not shown and Fig. 5). We studied the expression patterns of the following genes in qPCR experiments: the housekeeping gene ACTB as a non-ISG control, MX1, EIF2AK2 (PKR; Fig. 5A); OAS1, ISG15, STAT1 (Fig. 5B); IRF9, IFIT1 (ISG56), IFI6 (Fig. 5C); RSAD2 (Viperin), HERC5, HERC6 (Fig. 5D). All ISGs, with one exception (IFI6), demonstrated a characteristic expression pattern over 48 hours: IFN-α leads to a rapid increase of expression with a maximum after 8 hours of incubation followed by a decline in the signal. In contrast, IL28B up-regulates the same genes, showing a slower increase of induction that appears more sustained. On the other hand, we detected no changes in gene expression over time upon stimulation with either IFN-α or IL28B in expression of ACTB as a control gene.
Differences in Induction Kinetics by IFN-α and IL28B Are Altered by HCV Infection
We next investigated whether these general and reproducible patterns were preserved upon IFN-α or IL28B stimulation in the setting of infection with HCV. After all, genotypic variation related to IL28B profoundly determines therapeutic response in chronic HCV by a yet unidentified mechanism pointing towards an important role of the cytokine in the course of the disease. We treated both uninfected and HCV-infected Huh7.5.1 (after established infection over several days) cells in parallel with IFN-α or IL28B over 48 hours (Fig. 6A-E; Supporting Figure 1A,B). While the overall pattern of IL28B induced gene expression in HCV-infected Huh7.5.1 cells was similar compared to uninfected cells with a slow increase of signal over time, surprisingly, the typical IFN-α response was not preserved in infection: the pattern with early maximum followed by decline of the induction signal observed in uninfected Huh7.5.1 was blunted in the HCV-infected cells, and the course of gene expression over time became similar for IFN-α and IL28B-treated cells, reminiscent of a type III response. We assessed the effect of the cytokines on viral replication in the same samples over time and detected comparable antiviral effects (Supporting Figure 1C) and no clear pattern of increased or decreased expression for a selected number of representative ISGs (Supporting Figure 1D)
Differential Kinetics in Gene Expression Are Not Explained by Alteration in STAT1 Phosphorylation
Next, we investigated whether the observed RNA levels of ISGs were reflected in STAT1 phosphorylation patterns under the different conditions: we therefore studied phosphorylated STAT1 (pSTAT1) and STAT1 expression over time by western blot (Supporting Fig. 2). After optimization of relevant timepoints (time course up to 48 hours, data not shown) we saw an increase in the pSTAT1 signal with a maximum within 6 hours of stimulation followed by a decline. There were no apparent differences in the phosphorylation pattern observed in IFN-α or IL28B stimulated uninfected or infected cells. We conclude that STAT 1 phosphorylation patterns do not explain the distinct kinetic ISG mRNA patterns and that the basis for these distinct patterns potentially lie outside of the IFN signal transduction pathway.
In order to better understand the role and function of IL28B, we sought to characterize differences in gene induction by IFN-α and IL28B. While our comprehensive transcriptomic analysis in ex vivo cultured PHH did not primarily reveal distinct genes induced by IL28B, there were significant kinetic differences when looking at the expression profiles of the studied typical ISGs. For many of these genes, the response to IFN-α was a fast and sharp increase followed by a decline in expression within 24 hours, whereas the IL28B response was slower but more sustained. This led us to confirm and further investigate these patterns in a more stable cell culture model that is permissive for robust HCV infection, human hepatoma cells. In infected cells, we obtained a similar temporal response to IL28B and IFN-α. Therefore, interestingly, the kinetic difference we found previously was substantially altered after infection with HCV.
We compared IFN-α and IL28B induced genes in PHH over 24 hours in expression microarrays. When we sorted the genes by relevance in the IL28B induced samples, we found known IFN-α-stimulated genes. This concurs with the initial reports describing type III IFNs, in which the authors detected intracellular signal transduction by way of the same JAK-STAT pathway that transduces the type I IFN signal.[1, 2] Several publications analyze microarrays in PHH treated with IFN-α: In 2002 Radaeva et al. published gene expression in PHH detected on an Affymetrix chip comprising 12,000 known genes and found 44 up-regulated >2-fold, including MX1, the OAS family and PKR, and nine genes down-regulated by greater than 50%. He et al. compared transcriptomes of PHH after stimulation with IFN-α and IFN-γ at 6 hours and 18 hours. There were more IFN-α up-regulated genes at 6 hours than at 18 hours, whereas the opposite was true for IFN-γ. In HCV replicon cells, Marcello et al. compared the effects of IFN-α and IL29 (IFN-λ1) and found several different patterns of gene regulation over 24 hours. However, the replicon model is limited to intracellular stages of the viral life cycle and may not be directly comparable to our experiments. Another group found different kinetics of RSAD2 and IFI44 induction between IFN-α and IL28B stimulation in PHH, as well as overlapping and distinct genes when comparing transcriptomes. Based on our findings we speculate that genes previously described as being induced by solely one cytokine are ascribable to false negatives in the comparison samples, since the magnitude of induction appears to be considerably lower in PHH compared to cell lines and thus some genes have fallen below the threshold of significance. Interestingly, Doyle et al. treated HepG2 cells with IL-29 or IFN-α for 1, 6, and 24 hours. The gene expression profiles upon stimulation with both cytokines were very similar with induction of typical ISGs, like PKR and MX1 at 6 hours and declining signals thereafter. Therefore, in contrast to what we describe for IL28B, the kinetics for IL29 induced genes may rather resemble IFN-α induction.
PHH are exquisitely sensitive to perturbations, lose cell functions and viability rapidly in culture, and do not proliferate. Moreover, their use is limited by availability and quality of surgical specimens and the complex isolation procedure. It is important to note that due to the nature of hepatocyte extraction, there is a risk of contamination with other cell types in the PHH cultures. While on daily microscopic examination we were unable to detect any other cell types but hepatocytes in the cultures used for our studies, we cannot fully exclude that some of the effects that we see may be due to nonhepatocyte cells present in the cultures. Huh7.5.1 cells therefore appear as a valid model system to analyze kinetics. Based on our data from two lines of investigation, we conclude that IFN-α and IL28B exert their differential effects through temporal expression differences. We further hypothesize that these differences may play a critical role in the antiviral immune response and that IFN-α and IL28B may complement each other's effects. Cell type-dependent expression of IL28RA and production of type III IFNs may facilitate tissue-specific regulation of antiviral effects, therefore allowing for fine-tuned responses that are able to match the organ and cell specificity of viruses. There is accumulating evidence that the type III IFNs function as a first line of antiviral defense in epithelial tissues like the gut, human liver, and lung, e.g., upon infection with influenza virus, whereas lack of local receptor expression, for instance in the central nervous system (CNS), makes use of the system in other tissues unlikely.[22-26]
Viruses have developed sophisticated mechanisms to counteract the effects of IFN. HCV is notorious for its ability to evade host antiviral effector functions: mitochondrial antiviral-signaling protein (MAVS, also known as IPS-1), for example, is inactivated by the viral protease NS3/4, likely to diminish IFN induction. Further, HCV inhibits JAK-STAT signaling through a variety of mechanisms.[28-32]
In this study, we observed that HCV's modulation of the type I ISG response to resemble a type III response does not appear to be mediated by classical IFN signaling. Rather, they suggest that HCV may be acting through other, nonclassical mechanisms to sustain ISG expression, including induction of alternate transduction pathways or posttranscriptional regulation of ISGs. Blunting a rapid IFN response may be beneficial to survival of the virus. Once infection has stabilized, viral products may set up an effective antiinflammatory armamentarium that is able to suppress downstream effects of IFN-α. This is compatible with the clinical reality that signs of active inflammation early in the disease are predictive of viral clearance in HCV.[33, 34] This response may be important in many viral infections to rapidly induce innate antiviral action and protect the host from systemic spread of viruses.
We selected differing doses of IFN-α and IL28B for the PHH experiments because our pilot studies indicated that higher concentrations of IL28B were required to produce comparable levels of peak ISG induction. These data are supported by our findings in Fig. 3. This apparent dose disparity may be attributable to the two cytokine's differential affinity for their cognate receptors. We also performed experiments using much higher doses of IFN-α and lower doses of IL28B and found no difference in the induction kinetics of ISGs (not shown), suggesting that the two IFNs retain their fundamental induction patterns over a wide range of concentrations.
Mechanisms that could potentially explain outcome differences upon HCV infection in patients with different IL28B-related genotypes include: alterations in IL28B expression, mRNA splicing, half-life, or cytokine-receptor affinity or specificity. The literature on IL28A and IL28B expression levels is controversial, with some studies detecting slightly higher expression levels of the cytokines in the clearance associated genotype, e.g., in peripheral blood mononuclear cells (PBMCs),[9, 10] and others being unable to find any such correlations in PBMCs and liver tissue, respectively.[8, 17] An interesting recent contribution describes a novel gene that may be an additional member of the type III IFN family and contains a functional SNP related to both the IL28B genotype and outcome in HCV: Depending on genotype, a protein is either made or not made. Strikingly, the favorable IL28B genotype as well as viral clearance are associated with nonproduction of the protein. The functional role of this novel gene, named IFNL4 (IFN-λ4), and the mechanism of action of its protein are unknown. Another recent study detected the same polymorphism, but found a correlation with IL28B expression.
In summary, we demonstrate functional differences of IFN-α and IL28B by showing distinct kinetic induction patterns for many typical ISGs in hepatocytes. Furthermore, we demonstrate that the kinetic patterns of gene induction are altered during HCV infection. Given their common downstream signaling but temporal differences in gene induction, we speculate that IFN-α and IL28B play complementary roles with a massive, early IFN-α response and slower but more sustained gene induction by IL28B.
The authors thank F.V. Chisari (Scripps Research Institute, La Jolla, CA) for Huh7.5.1 cells, T. Wakita (National Institute for Infectious Diseases, Tokyo, Japan), and Charles M. Rice (Rockefeller University, New York, NY) for the infectious HCV strains JFH1 and Jc1Gluc. Normal human hepatocytes were obtained through the Liver Tissue Cell Distribution System (S.C. Strom, University of Pittsburgh, Pittsburgh, PA) which was funded by NIH Contract #N01-DK-7-004/HHSN26l7200700004C. We thank David Goldstein (Duke University, NC) for facilitating the microarray experiments and T.F. Baumert (INSERM U748, Strasbourg, France) for helpful suggestions.